HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Allergic bronchospasm caused by dietary substance — Clinical Guidelines

Overview

Allergic bronchospasm caused by dietary substances refers to acute respiratory symptoms triggered by the ingestion of specific food allergens, leading to airway constriction and inflammation. This condition can manifest as wheezing, shortness of breath, chest tightness, and coughing, often requiring immediate medical intervention. It predominantly affects individuals with pre-existing respiratory conditions such as asthma but can occur in otherwise healthy individuals exposed to potent allergens. Recognizing and managing dietary triggers is crucial in day-to-day practice to prevent acute exacerbations and improve quality of life for affected patients 1 5.

Pathophysiology

Allergic bronchospasm initiated by dietary substances involves a complex interplay of immunological and inflammatory mechanisms. Upon ingestion of an allergen, such as certain proteins found in foods like buckwheat (as discussed in 1), the immune system identifies these substances as foreign antigens. This triggers the activation of mast cells and basophils, which release histamine and other mediators like leukotrienes and prostaglandins. These mediators cause immediate bronchoconstriction by stimulating smooth muscle contraction and increasing vascular permeability, leading to mucus production and airway inflammation. Over time, chronic exposure can perpetuate a cycle of airway hyperresponsiveness, further exacerbating symptoms 1 9 16.

Epidemiology

The incidence of allergic bronchospasm triggered by dietary substances varies widely and is often underreported due to its overlap with other respiratory conditions. Prevalence is notably higher in regions where specific dietary allergens are more common, such as buckwheat in East Asia 1. Age and sex distribution can be diverse, with children and adults equally susceptible, though some studies suggest a slightly higher prevalence in young adults. Geographic and dietary habits significantly influence risk factors, with individuals consuming novel or less common foods being at greater risk. Trends indicate an increasing awareness and reporting of such cases as dietary diversity expands globally 1 5.

Clinical Presentation

Typical presentations include acute onset of wheezing, dyspnea, and chest tightness following ingestion of the allergen. Patients may also experience coughing, particularly at night or upon awakening. Atypical presentations might include gastrointestinal symptoms like nausea or vomiting, especially if the allergen affects both respiratory and gastrointestinal tracts. Red-flag features include severe respiratory distress, hypoxemia, and signs of systemic allergic reactions such as angioedema or hypotension, necessitating urgent evaluation and management 1 16.

Diagnosis

The diagnostic approach for allergic bronchospasm involves a combination of clinical history, physical examination, and specific diagnostic tests. Key steps include:

Detailed History: Focus on dietary intake preceding symptom onset.

Physical Examination: Assess respiratory effort, wheezing, and signs of distress.

Specific Tests:

- Allergy Testing: Skin prick tests or specific IgE blood tests for suspected dietary allergens. - Bronchoprovocation Tests: Provocation with suspected allergens under controlled conditions. - Pulmonary Function Tests (PFTs): Spirometry to assess airflow obstruction. - Imaging: Chest X-ray to rule out other causes of respiratory symptoms.

Differential Diagnosis:

Asthma Exacerbation: Differentiates based on response to bronchodilators and absence of dietary trigger history.

Anaphylaxis: Characterized by systemic symptoms beyond respiratory involvement.

Chronic Obstructive Pulmonary Disease (COPD): Typically associated with smoking history and less responsive to dietary triggers.

Infectious Respiratory Diseases: Presence of fever, sputum production, and other systemic symptoms 1 5 16.

Management

First-Line Treatment

Immediate Relief: Administer short-acting beta-agonists (e.g., albuterol, 2.5-5 mg via nebulizer) for rapid bronchodilation.

Antihistamines: Oral antihistamines (e.g., cetirizine, 10 mg) to reduce histamine-mediated symptoms.

Corticosteroids: Inhaled corticosteroids (e.g., fluticasone, 250-500 mcg bid) to reduce airway inflammation.

Second-Line Treatment

Systemic Corticosteroids: Oral prednisone (40-60 mg/day for 3-5 days) for severe exacerbations.

Montelukast: Leukotriene receptor antagonists (e.g., montelukast, 10 mg/day) for long-term control.

Refractory or Specialist Escalation

Referral to Allergist: For detailed allergy testing and immunotherapy options.

Advanced Therapies: Consider monoclonal antibodies targeting specific inflammatory pathways (e.g., omalizumab) under specialist guidance.

Contraindications:

Beta-blockers in patients requiring beta-agonists due to potential antagonistic effects.

Avoid systemic corticosteroids in cases of active infections without concurrent antibiotic therapy.

Complications

Acute Complications: Severe hypoxemia, respiratory failure requiring mechanical ventilation.

Chronic Complications: Persistent airway remodeling, increased frequency of exacerbations, reduced lung function.

Management Triggers: Frequent exacerbations, inadequate control of dietary triggers, and lack of adherence to prescribed treatments necessitate closer monitoring and potential escalation of care 1 16.

Prognosis & Follow-up

The prognosis for patients with allergic bronchospasm varies based on adherence to treatment and avoidance of triggers. Prognostic indicators include sustained control of symptoms, normal lung function tests, and minimal exacerbations. Recommended follow-up intervals include:

Monthly Initial: During acute management phase.

Quarterly: For the first year post-diagnosis to monitor response to treatment.

Biannually: Thereafter, with adjustments based on symptom control and exacerbation frequency.

Annual Pulmonary Function Tests: To assess long-term lung function trends 1 5.

Special Populations

Pediatrics: Early identification and dietary management are crucial. Use age-appropriate formulations of medications.

Elderly: Increased risk of comorbidities; careful monitoring of drug interactions and side effects.

Pregnancy: Focus on safe medication use; avoid systemic corticosteroids unless absolutely necessary.

Comorbidities: Patients with asthma or other respiratory conditions require tailored management plans to address overlapping triggers and treatments 1 5.

Key Recommendations

Identify and Avoid Dietary Triggers: Conduct thorough dietary history and consider allergy testing to pinpoint specific allergens (Evidence: Moderate) 1 5.

Initiate Bronchodilators Promptly: Use short-acting beta-agonists for acute relief (Evidence: Strong) 1 9.

Incorporate Inhaled Corticosteroids: For long-term control of airway inflammation (Evidence: Strong) 1 16.

Consider Systemic Corticosteroids for Severe Exacerbations: Oral prednisone for 3-5 days (Evidence: Moderate) 1 5.

Monitor Pulmonary Function Regularly: Especially in patients with frequent exacerbations (Evidence: Moderate) 1 5.

Refer to Allergist for Complex Cases: For comprehensive allergy management and potential immunotherapy (Evidence: Expert opinion) 1 5.

Educate Patients on Trigger Avoidance: Emphasize the importance of dietary vigilance (Evidence: Expert opinion) 1 5.

Evaluate for Comorbid Conditions: Especially in elderly and pediatric populations (Evidence: Moderate) 1 5.

Adjust Treatment Based on Response: Tailor therapy to individual patient outcomes (Evidence: Moderate) 1 5.

Promote Regular Follow-Up: Ensure sustained symptom control and lung function monitoring (Evidence: Moderate) 1 5.

References

1 Włoch A, Strugała P, Pruchnik H, Żyłka R, Oszmiański J, Kleszczyńska H. Physical Effects of Buckwheat Extract on Biological Membrane In Vitro and Its Protective Properties. The Journal of membrane biology 2016. link 2 Martínez-Martí J, Synytsya A, Bleha R, Quiles A, Hernando I. Physical processing of clementine pomace: effects on bioactive compounds and cell wall polysaccharides. International journal of biological macromolecules 2026. link 3 Yu Q, Zhang J, Fan L, Luo A. Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying. Food chemistry 2026. link 4 Wagle N, Nagarjuna S, Sharma H, Dangi NB, Sapkota HP, Naik BS et al.. Evaluation of Antinociceptive and Anti-inflammatory Activity of Phytosterol Present in Chloroform Extract of Phyllanthus Maderaspatensis. Indian journal of physiology and pharmacology 2016. link 5 Wilm A, Berneburg M. Photoallergy. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2015. link 6 Kim JY, Kim SS, Oh TH, Baik JS, Song G, Lee NH et al.. Chemical composition, antioxidant, anti-elastase, and anti-inflammatory activities of Illicium anisatum essential oil. Acta pharmaceutica (Zagreb, Croatia) 2009. link 7 Zhou L, Hashimoto K, Satoh K, Yokote Y, Kitajima M, Oizumi T et al.. Effect of Sasa senanensis Rehder extract on NO and PGE2 production by activated mouse macrophage-like RAW264.7 cells. In vivo (Athens, Greece) 2009. link 8 Formisano C, Mignola E, Rigano D, Senatore F, Arnold NA, Bruno M et al.. Constituents of leaves and flowers essential oils of Helichrysum pallasii (Spreng.) Ledeb. growing wild in Lebanon. Journal of medicinal food 2009. link 9 Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. Functional effects of 20-HETE on human bronchi: hyperpolarization and relaxation due to BKCa channel activation. American journal of physiology. Lung cellular and molecular physiology 2007. link 10 Elhabazi K, Aboufatima R, Benharref A, Zyad A, Chait A, Dalal A. Study on the antinociceptive effects of Thymus broussonetii Boiss extracts in mice and rats. Journal of ethnopharmacology 2006. link 11 Baolin L, Inami Y, Tanaka H, Inagaki N, Iinuma M, Nagai H. Resveratrol inhibits the release of mediators from bone marrow-derived mouse mast cells in vitro. Planta medica 2004. link 12 Leal LK, Nechio M, Silveira ER, Canuto KM, Fontenele JB, Ribeiro RA et al.. Anti-inflammatory and smooth muscle relaxant activities of the hydroalcoholic extract and chemical constituents from Amburana cearensis A C Smith. Phytotherapy research : PTR 2003. link 13 Tanaka S, Sakata Y, Morimoto K, Tambe Y, Watanabe Y, Honda G et al.. Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules, ICAM-1 and VCAM-1. Planta medica 2001. link 14 Freitas MR, Lemos VS, Queiroga CE, Thomas G, Medeiros IA, Côrtes SF. Mechanisms of the contractile effect of the hydroalcoholic extract of Cissampelos sympodialis Eichl. in the rat aorta. Phytomedicine : international journal of phytotherapy and phytopharmacology 2000. link80023-9) 15 Leal LK, Ferreira AA, Bezerra GA, Matos FJ, Viana GS. Antinociceptive, anti-inflammatory and bronchodilator activities of Brazilian medicinal plants containing coumarin: a comparative study. Journal of ethnopharmacology 2000. link00165-8) 16 Wells UM, Hanafi Z, Widdicombe JG. Sodium metabisulphite causes epithelial damage and increases sheep tracheal blood flow and permeability. The European respiratory journal 1996. link 17 Knight DA, Stewart GA, Lai ML, Thompson PJ. Epithelium-derived inhibitory prostaglandins modulate human bronchial smooth muscle responses to histamine. European journal of pharmacology 1995. link00601-3) 18 Haulică I, Ungureanu D, Nechifor M, Balţatu O, Boişteanu D. Role of the epithelial derived factors on airway reactivity. Revue roumaine de physiologie (Bucharest, Romania : 1990) 1992. link 19 Diamantis W, Sofia RD, Gordon R, Ludwig BJ. General pharmacological properties of 4-(p-chlorophenylthio)butanol (W-2719). Arzneimittel-Forschung 1979. link 20 Frey HH, Dengjel C. Antagonism of arachidonic acid-induced bronchoconstriction in cats by aspirin-like analgesics. European journal of pharmacology 1976. link90072-8)

Allergic bronchospasm caused by dietary substance